Drug Database
Back to search

Netherlands· NL-20aab0bda1a0

Proleukin 18 x 1.000.000 IE poeder voor oplossing voor injectie of infusie

A aldesleukin product containing aldesleukine, registered in Netherlands by Iovance Biotherapeutics B.V.. The same ATC class is registered in 10 of our 19 countries.

ATC L03AC01

Checked against CBG-MEB (Netherlands) on

Informational only — not a medical device.

SOURCE REGISTER · NLCBG-MEB (Netherlands)normalisedProleukin 18 x 1.000.000 IE poeder vo…ATCL03AC01REGISTER NO.NL-20aab0bda1a0PACKS LISTED1CHECKEDSeptember 29, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about aldesleukineAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Aldesleukin is registered in 10 of 19 countries.

Countries holding a registration under ATC L03AC01 (aldesleukin), each read from that country’s own register.

  • This record: Netherlands, from CBG-MEB (Netherlands)
  • 6 of them publish a price we can compare per daily dose
Search aldesleukin products by name

Aldesleukin · ATC L03AC01

10 / 19 countries

  • Belgiumprice
  • Canada
  • Finlandprice
  • Franceprice
  • Germany
  • Netherlands
  • Norwayprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

CBG-MEB (Netherlands)
Active substance
ALDESLEUKINE
Manufacturer
Iovance Biotherapeutics B.V.
Country
Netherlands (NL)
ATC code
L03AC01
ATC class
Aldesleukin
Defined daily dose
0.2 mg, P
Reimbursed
Not published by this register
Source register
CBG-MEB (Netherlands)
Last checked
September 29, 2026

Packs & prices · 1

  • cbg_meb_id
    13354

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

472 interactions on record for aldesleukin.

Graded by severity as the source publishes them — 46 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check aldesleukin against other medicinesHow interaction checks work

Aldesleukin · interactions on record

472 records

  • 46 severe
  • 411 moderate
  • 15 minor

Most severe, free to view

  • MipomersenC10AX11severe
  • LomitapideC10AX12severe
  • CidofovirJ05AB12severe
  • DacarbazineL01AX04severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Aldesleukin in 10 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All aldesleukin products

Authorised across Europe · EMA

The same active substance is authorised in 6 EEA countries. Names it is sold under:

  • Austria · Proleukin
  • Germany · Proleukin S
  • Spain · Proleukin
  • France · Proleukin
  • United Kingdom (Northern Ireland) · Proleukin
  • Italy · Proleukin

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/c0ba2d67-7c3c-4e35-b0c2-7ffe6d5892f4
GET /v1/drugs/c0ba2d67-7c3c-4e35-b0c2-7ffe6d5892f4?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Poeder voor oplossing voor injectie of infusie",
  "route": "Intraveneus gebruik, Subcutaan gebruik",
  "soort": "RVG",
  "source": "cbg_meb",
  "smpc_url": "https://www.geneesmiddeleninformatiebank.nl/smpc/h13354_smpc.pdf",
  "strength": null,
  "atc_label": "Aldesleukin",
  "detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/rvg13354",
  "excipients": [
    "DINATRIUMWATERSTOFFOSFAAT 2-WATER (E 339)",
    "MANNITOL (D-) (E 421)",
    "NATRIUMDIWATERSTOFFOSFAAT 2-WATER (E 339)",
    "NATRIUMLAURILSULFAAT",
    "STIKSTOF (HEAD SPACE) (E 941)"
  ],
  "substances": [
    "ALDESLEUKINE"
  ],
  "leaflet_url": "https://www.geneesmiddeleninformatiebank.nl/bijsluiters/h13354.pdf",
  "authorised_at": "1989/07/17",
  "procedure_number": "NL/H/0005/001",
  "dispensing_status": "Uitsluitend recept",
  "registration_number": "13354",
  "additional_monitoring": "N"
}
API referenceMCP serverPlans

See everything about aldesleukin.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console